Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gabapentin + methylprednisolone
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Gabapentin + methylprednisolone is a combination therapy investigated by Jagiellonian University as a pre-emptive analgesic regimen for the management of postoperative pain, specifically in elderly patients undergoing total knee arthroplasty (TKA). Methylprednisolone is a synthetic glucocorticoid that reduces systemic inflammation and immune response by activating glucocorticoid receptors, thereby lowering levels of inflammatory markers like C-reactive protein (CRP). Gabapentin is an anticonvulsant that binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, inhibiting the release of excitatory neurotransmitters involved in pain signaling. The combination aims to provide synergistic pain relief, reduce the requirement for postoperative opioids, and accelerate convalescence by targeting both inflammatory and neuropathic pain pathways before surgical trauma occurs.
- Other names
- Pre-emptive Gabapentin and MethylprednisoloneMethylprednisolone and Gabapentin combination
02
Targets
GR (Glucocorticoid receptor)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)
Beyond the preview
Go deeper on gabapentin + methylprednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gabapentin + methylprednisolone.